Benfotiamine: Commentary and update on recent studies

A. Stirban, S. Tesfaye, I. Gurieva, L. Czupryniak, B. N. Mankovsky, V. Spallone, I. A. Veresiu, O. Schnell, D. Ziegler, P. Kempler

Research output: Contribution to journalArticle

Abstract

The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.

Original languageEnglish
Pages (from-to)203-206
Number of pages4
JournalDiabetes, Stoffwechsel und Herz
Volume23
Issue number4
Publication statusPublished - Aug 20 2014

Fingerprint

Hyperglycemia
Thiamine
Prodrugs
Diabetes Complications
Blood Vessels
Oxidative Stress
benphothiamine
Research

Keywords

  • Benfotiamine
  • Diabetes
  • Hyperglycaemia
  • Neuropathy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Stirban, A., Tesfaye, S., Gurieva, I., Czupryniak, L., Mankovsky, B. N., Spallone, V., ... Kempler, P. (2014). Benfotiamine: Commentary and update on recent studies. Diabetes, Stoffwechsel und Herz, 23(4), 203-206.

Benfotiamine : Commentary and update on recent studies. / Stirban, A.; Tesfaye, S.; Gurieva, I.; Czupryniak, L.; Mankovsky, B. N.; Spallone, V.; Veresiu, I. A.; Schnell, O.; Ziegler, D.; Kempler, P.

In: Diabetes, Stoffwechsel und Herz, Vol. 23, No. 4, 20.08.2014, p. 203-206.

Research output: Contribution to journalArticle

Stirban, A, Tesfaye, S, Gurieva, I, Czupryniak, L, Mankovsky, BN, Spallone, V, Veresiu, IA, Schnell, O, Ziegler, D & Kempler, P 2014, 'Benfotiamine: Commentary and update on recent studies', Diabetes, Stoffwechsel und Herz, vol. 23, no. 4, pp. 203-206.
Stirban A, Tesfaye S, Gurieva I, Czupryniak L, Mankovsky BN, Spallone V et al. Benfotiamine: Commentary and update on recent studies. Diabetes, Stoffwechsel und Herz. 2014 Aug 20;23(4):203-206.
Stirban, A. ; Tesfaye, S. ; Gurieva, I. ; Czupryniak, L. ; Mankovsky, B. N. ; Spallone, V. ; Veresiu, I. A. ; Schnell, O. ; Ziegler, D. ; Kempler, P. / Benfotiamine : Commentary and update on recent studies. In: Diabetes, Stoffwechsel und Herz. 2014 ; Vol. 23, No. 4. pp. 203-206.
@article{d6d081369e2e4b00891429fc156ec923,
title = "Benfotiamine: Commentary and update on recent studies",
abstract = "The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.",
keywords = "Benfotiamine, Diabetes, Hyperglycaemia, Neuropathy",
author = "A. Stirban and S. Tesfaye and I. Gurieva and L. Czupryniak and Mankovsky, {B. N.} and V. Spallone and Veresiu, {I. A.} and O. Schnell and D. Ziegler and P. Kempler",
year = "2014",
month = "8",
day = "20",
language = "English",
volume = "23",
pages = "203--206",
journal = "Diabetes und Stoffwechsel",
issn = "1861-7603",
publisher = "Verlag Kirchheim and Co. GmbH",
number = "4",

}

TY - JOUR

T1 - Benfotiamine

T2 - Commentary and update on recent studies

AU - Stirban, A.

AU - Tesfaye, S.

AU - Gurieva, I.

AU - Czupryniak, L.

AU - Mankovsky, B. N.

AU - Spallone, V.

AU - Veresiu, I. A.

AU - Schnell, O.

AU - Ziegler, D.

AU - Kempler, P.

PY - 2014/8/20

Y1 - 2014/8/20

N2 - The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.

AB - The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.

KW - Benfotiamine

KW - Diabetes

KW - Hyperglycaemia

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84906837618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906837618&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84906837618

VL - 23

SP - 203

EP - 206

JO - Diabetes und Stoffwechsel

JF - Diabetes und Stoffwechsel

SN - 1861-7603

IS - 4

ER -